$SNOA
Sonoma Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000168316823007982 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $3.138M $2.731M
YoY Change 6.59% -18.01%
Cost Of Revenue $1.678M $1.741M
YoY Change -20.59% -12.73%
Gross Profit $1.460M $990.0K
YoY Change 75.69% -25.9%
Gross Profit Margin 46.53% 36.25%
Selling, General & Admin $1.703M $1.662M
YoY Change -36.1% -19.59%
% of Gross Profit 116.64% 167.88%
Research & Development $601.0K $536.0K
YoY Change
% of Gross Profit 41.16% 54.14%
Depreciation & Amortization $45.00K $40.00K
YoY Change 40.63% 42.86%
% of Gross Profit 3.08% 4.04%
Operating Expenses $2.304M $2.198M
YoY Change -13.55% 6.34%
Operating Profit -$844.0K -$1.208M
YoY Change -53.98% 65.25%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$79.00K -$90.00K
YoY Change 8.22% -52.38%
Pretax Income -$923.0K -$1.298M
YoY Change -51.55% 41.55%
Income Tax -$57.00K $186.0K
% Of Pretax Income
Net Earnings -$866.0K -$1.484M
YoY Change -55.34% 45.92%
Net Earnings / Revenue -27.6% -54.34%
Basic Earnings Per Share -$0.08 -$0.29
Diluted Earnings Per Share -$0.08 -$0.29
COMMON SHARES
Basic Shares Outstanding 13.68M shares 5.143M shares
Diluted Shares Outstanding 10.91M shares 5.164K shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.406M $2.140M
YoY Change -8.66% -36.14%
Cash & Equivalents $2.406M $2.137M
Short-Term Investments
Other Short-Term Assets $4.265M $4.650M
YoY Change 23.55% 31.73%
Inventory $2.955M $2.513M
Prepaid Expenses
Receivables $2.876M $2.223M
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.50M $11.52M
YoY Change 11.31% -7.08%
LONG-TERM ASSETS
Property, Plant & Equipment $397.0K $433.0K
YoY Change 26.43% 41.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.00K $75.00K
YoY Change -74.68% -68.49%
Total Long-Term Assets $2.116M $2.119M
YoY Change -21.51% -17.52%
TOTAL ASSETS
Total Short-Term Assets $12.50M $11.52M
Total Long-Term Assets $2.116M $2.119M
Total Assets $14.62M $13.64M
YoY Change 4.95% -8.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $864.0K $987.0K
YoY Change -33.64% -8.1%
Accrued Expenses $2.028M $1.920M
YoY Change -18.13% -7.29%
Deferred Revenue
YoY Change
Short-Term Debt $44.00K $170.0K
YoY Change -25.76%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.074M $3.239M
YoY Change -21.86% -8.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $4.852M $4.720M
YoY Change 9.77% 7.3%
Total Long-Term Liabilities $4.852M $4.720M
YoY Change 32246.67% 31366.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.074M $3.239M
Total Long-Term Liabilities $4.852M $4.720M
Total Liabilities $7.926M $7.960M
YoY Change -5.29% 0.24%
SHAREHOLDERS EQUITY
Retained Earnings -$193.3M -$192.4M
YoY Change 2.7% 3.3%
Common Stock $202.8M $201.2M
YoY Change 2.45% 1.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.692M $5.675M
YoY Change
Total Liabilities & Shareholders Equity $14.62M $13.64M
YoY Change 4.95% -8.87%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$866.0K -$1.484M
YoY Change -55.34% 45.92%
Depreciation, Depletion And Amortization $45.00K $40.00K
YoY Change 40.63% 42.86%
Cash From Operating Activities -$1.100M -$1.230M
YoY Change 216.09% -32.79%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.314M -120.0K
YoY Change -513.21% -32.58%
NET CHANGE
Cash From Operating Activities -1.100M -1.230M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 1.314M -120.0K
Net Change In Cash 214.0K -1.350M
YoY Change -133.86% -38.5%
FREE CASH FLOW
Cash From Operating Activities -$1.100M -$1.230M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.100M -$1.230M
YoY Change 190.24% -31.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001367083
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33216
dei Entity Registrant Name
EntityRegistrantName
SONOMA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0423298
dei Entity Address Address Line1
EntityAddressAddressLine1
5445 Conestoga Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
Boulder
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80301
dei City Area Code
CityAreaCode
(800)
dei Local Phone Number
LocalPhoneNumber
759-9305
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
SNOA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13679333 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2137000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3820000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2223000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2572000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
2513000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
2858000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4395000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4308000 usd
CY2023Q3 SNOA Deferred Consideration Net Current
DeferredConsiderationNetCurrent
248000 usd
CY2023Q1 SNOA Deferred Consideration Net Current
DeferredConsiderationNetCurrent
240000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
11516000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
13798000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
433000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
488000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
350000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
418000 usd
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
840000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
949000 usd
CY2023Q3 SNOA Deferred Consideration Net Noncurrent
DeferredConsiderationNetNoncurrent
421000 usd
CY2023Q1 SNOA Deferred Consideration Net Noncurrent
DeferredConsiderationNetNoncurrent
505000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73000 usd
CY2023Q3 us-gaap Assets
Assets
13635000 usd
CY2023Q1 us-gaap Assets
Assets
16231000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
987000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
841000 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
1702000 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities
AccountsPayableAndOtherAccruedLiabilities
2029000 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
101000 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000 usd
CY2023Q3 SNOA Contract With Customer Liability Current Invekra
ContractWithCustomerLiabilityCurrentInvekra
61000 usd
CY2023Q1 SNOA Contract With Customer Liability Current Invekra
ContractWithCustomerLiabilityCurrentInvekra
60000 usd
CY2023Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
172000 usd
CY2023Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
431000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3239000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3717000 usd
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
114000 usd
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
140000 usd
CY2023Q3 SNOA Withholding Tax Payable
WithholdingTaxPayable
4473000 usd
CY2023Q1 SNOA Withholding Tax Payable
WithholdingTaxPayable
4235000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
134000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
162000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
7960000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
8254000 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
24000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
24000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5179333 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5179333 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4933550 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4933550 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
201210000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
200904000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192416000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189514000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3120000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3418000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5675000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7977000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13635000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16231000 usd
CY2023Q3 us-gaap Revenues
Revenues
2731000 usd
CY2022Q3 us-gaap Revenues
Revenues
3331000 usd
us-gaap Revenues
Revenues
6158000 usd
us-gaap Revenues
Revenues
7314000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1741000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1795000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3964000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4132000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
990000 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
1536000 usd
us-gaap Gross Profit
GrossProfit
2194000 usd
us-gaap Gross Profit
GrossProfit
3182000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
536000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
200000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
861000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2902000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1904000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
-213000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
-34000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
406000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1662000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2067000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3781000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4362000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2198000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2267000 usd
us-gaap Operating Expenses
OperatingExpenses
4642000 usd
us-gaap Operating Expenses
OperatingExpenses
4768000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1208000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-731000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2448000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1586000 usd
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-90000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-186000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-301000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-253000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1298000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-917000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2749000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1839000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
186000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
153000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1484000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2902000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1904000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5164 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5164 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3101 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3101 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5051 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5051 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3101 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3101 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1484000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
298000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
-99000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1697000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-1051000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2604000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2003000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2902000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1904000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
307000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
327000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
144000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-139000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-375000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
160000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-403000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
447000 usd
SNOA Increase Decrease In Deferred Consideration Net Of Discount
IncreaseDecreaseInDeferredConsiderationNetOfDiscount
104000 usd
SNOA Increase Decrease In Deferred Consideration Net Of Discount
IncreaseDecreaseInDeferredConsiderationNetOfDiscount
82000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-47000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-397000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-79000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-21000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
132000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-558000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-353000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-44000 usd
SNOA Increase Decrease In Withholding Tax Payable
IncreaseDecreaseInWithholdingTaxPayable
238000 usd
SNOA Increase Decrease In Withholding Tax Payable
IncreaseDecreaseInWithholdingTaxPayable
175000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-79000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-23000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1149000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1446000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3363000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000 usd
us-gaap Payments For Other Deposits
PaymentsForOtherDeposits
-0 usd
us-gaap Payments For Other Deposits
PaymentsForOtherDeposits
162000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-210000 usd
SNOA Payment On Atm Agreement Offering
PaymentOnAtmAgreementOffering
5000 usd
SNOA Payment On Atm Agreement Offering
PaymentOnAtmAgreementOffering
-0 usd
SNOA Payments On Ppp Loan
PaymentsOnPppLoan
-0 usd
SNOA Payments On Ppp Loan
PaymentsOnPppLoan
120000 usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
0 usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
15000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
259000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
460000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-264000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-565000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1683000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4045000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3820000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7396000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2137000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3351000 usd
us-gaap Interest Paid Net
InterestPaidNet
10000 usd
us-gaap Interest Paid Net
InterestPaidNet
8000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7977000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-5000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
177000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
511000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1418000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
7242000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
130000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-213000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1484000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
5675000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
8697000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
214000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-65000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-887000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7959000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
108000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
5000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-34000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1017000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7021000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1484000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2902000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1904000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192416000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189514000 usd
CY2023Q3 SNOA Working Capital
WorkingCapital
8277000 usd
CY2023Q1 SNOA Working Capital
WorkingCapital
10081000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2137000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3820000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1446000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3363000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zCm1ToLV3oV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86D_zrgptKxziNP8">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zfsRbYpCqTth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zsmqZxdyWpoc">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and six months ended September 30, 2023, the Company aligned its accounting policy and conformed its prior presentation of certain costs it views as research and development efforts. These costs are now included in research and development, whereas they were previously included in cost of revenues. During the three and six months ended September 30, 2022, the Company reclassified $<span id="xdx_904_ecustom--IncreaseResearchAndDevelopmentInProcess_pn3p0_c20230701__20230930_zdRKYwScKfK2" title="Increase research and development in process">200,000</span> and $<span id="xdx_907_ecustom--IncreaseResearchAndDevelopmentInProcess_pn3p0_c20230401__20230930_zpuTfc0kZNc" title="Increase research and development in process">400,000</span>, respectively, from cost of revenues to research and development. The reclassification in the prior periods increased research and development and decreased cost of revenues by the same amount. The reclassification had no impact on total operating costs, earnings from operations, net earnings, earnings per share or total equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q3 SNOA Increase Research And Development In Process
IncreaseResearchAndDevelopmentInProcess
200000 usd
SNOA Increase Research And Development In Process
IncreaseResearchAndDevelopmentInProcess
400000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1484000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1017000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2902000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1904000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5164 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5164 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3101 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3101 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5051 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5051 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3101 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3101 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
668 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
560 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
668 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
560 shares
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q3 SNOA Allowance For Sales Discounts Rebates Distributor Fees And Returns
AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns
24000 usd
CY2023Q1 SNOA Allowance For Sales Discounts Rebates Distributor Fees And Returns
AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns
16000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
162000 usd
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
280000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
236000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1493000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1764000 usd
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1020000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1094000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
2513000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
2858000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
350000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
418000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
216000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
256000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
134000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
216000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
79000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P19Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0600 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
81000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
144000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
157000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
391000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
41000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
350000 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
24000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
130000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
113000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
307000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
327000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3331000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6158000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7314000 usd
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1261 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0512 pure
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2731000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3331000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6158000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7314000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2731000 usd

Files In Submission

Name View Source Status
snoa-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
snoa-20230930_def.xml Edgar Link unprocessable
0001683168-23-007982-index-headers.html Edgar Link pending
0001683168-23-007982-index.html Edgar Link pending
0001683168-23-007982.txt Edgar Link pending
0001683168-23-007982-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snoa-20230930.xsd Edgar Link pending
sonoma_ex1020.htm Edgar Link pending
sonoma_ex1038.htm Edgar Link pending
sonoma_ex3101.htm Edgar Link pending
sonoma_ex3102.htm Edgar Link pending
sonoma_ex3201.htm Edgar Link pending
sonoma_i10q-093023.htm Edgar Link pending
snoa-20230930_cal.xml Edgar Link unprocessable
snoa-20230930_pre.xml Edgar Link unprocessable
sonoma_i10q-093023_htm.xml Edgar Link completed